Back to search results

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Heart Transplantation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Spain

    Contact: Study coordinator (Rafael Correa-Rocha, PhD) · rafael.correa@iisgm.com
    Esther Bernaldo-de-Quiros, MsC (Sub-investigator)
    Marjorie Pion, PhD (Sub-investigator)
    Diana Hernández-Flórez, PhD (Sub-investigator)
    Marta Martínez-Bonet, PhD (Sub-investigator)
    Manuela Camino Lopez, MD PhD (Sub-investigator)
    Juan Miguel Gil-Jaurena, MD (Sub-investigator)
    Nuria Gil Villanueva, MD PhD (Sub-investigator)
    Carlos Pardo, MD PhD (Sub-investigator)
    Mª Eugenia Fernández-Santos, PhD (Sub-investigator)
    Ramón Pérez-Caballero, MD PhD (Sub-investigator)
Study leads

  • Rafael Correa-Rocha, PhD

    Principal Investigator

    Hospital General Universitario Gregorio Marañon

View source on ClinicalTrials.gov(opens in a new tab)